Management of Melanoma Brain Metastasis

  • C. BoutrosEmail author
  • C. Robert


In the past decades, local therapies including surgery, whole-brain radiation therapy, and stereotactic radiosurgery were considered the pillar of metastatic brain metastasis (MBM) management, although their benefit in terms of overall survival was never demonstrated. Advances in understanding the biology and molecular pathways implicated in melanoma biology and consecutive improvements in metastatic melanoma treatment using anti-BRAF-based targeted therapies for BRAFV600-mutant melanoma as well as immune checkpoint immunotherapy have generated considerable interest in evaluating these novel systemic therapies in treating MBM (Table 22.1).


  1. 1.
    Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087–95.CrossRefGoogle Scholar
  2. 2.
    Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–51.CrossRefGoogle Scholar
  3. 3.
    Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–9.CrossRefGoogle Scholar
  4. 4.
    Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64.CrossRefGoogle Scholar
  5. 5.
    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.CrossRefGoogle Scholar
  6. 6.
    Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459–65.CrossRefGoogle Scholar
  7. 7.
    Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 2012;13(9):879–86.CrossRefGoogle Scholar
  8. 8.
    Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, et al. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol. 2015;26(4):798–803.CrossRefGoogle Scholar
  9. 9.
    Di Giacomo AM, Annesi D, Ascierto PA, Calabrò L, Chiarion-Sileni V, Danielli R, et al. A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial. J Clin Oncol. 2015;33.(suppl:9090.CrossRefGoogle Scholar
  10. 10.
    Long GV, Atkinson V, Menzies AM, Lo S, Guminski AD, Brown MP, et al. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). J Clin Oncol. 2017;35.(Suppl:9508.CrossRefGoogle Scholar
  11. 11.
    Tawbi H, Forsyth PA, Algazi AP, Hamid O, Hodi FS, Moschos SJ, et al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. J Clin Oncol. 2017;35.(Suppl:9507.CrossRefGoogle Scholar
  12. 12.
    Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976–83.CrossRefGoogle Scholar
  13. 13.
    Nardin C, Mateus C, Texier M, Lanoy E, Hibat-Allah S, Ammari S, Robert C, Dhermain F. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases. Melanoma Res. 2018;28(2):111–9.CrossRefGoogle Scholar
  14. 14.
    Wolf A, Zia S, Verma R, Pavlick A, Wilson M, Golfinos JG, et al. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. J Neurooncol. 2016;127(3):607–15.CrossRefGoogle Scholar
  15. 15.
    Liniker E, Menzies AM, Kong BY, Cooper A, Ramanujam S, Lo S, et al. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology. 2016;5(9):e1214788.CrossRefGoogle Scholar
  16. 16.
    Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20.CrossRefGoogle Scholar
  17. 17.
    Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–52.CrossRefGoogle Scholar
  18. 18.
    Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, et al. Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol. 2018:JCO2017751644.. [Epub ahead of print].Google Scholar
  19. 19.
    Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015;16(6):e270–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Dermatology Unit, Department of MedicineGustave Roussy Cancer CampusVillejuifFrance
  2. 2.Outpatient Clinic, Department of MedicineGustave Roussy Cancer CampusVillejuifFrance
  3. 3.University Paris-Saclay, Faculty of MedicineKremlin-BicêtreFrance
  4. 4.INSERM Unit U981VillejuifFrance

Personalised recommendations